marginscan
(2)
Craig Davis
Craig Davis is the President and CEO of NovaScan, a Chicago-based clinical-stage oncology company building a low-cost, point-of-care platform that uses bioimpedance and machine learning to detect and stratify cancer in real time. A medtech executive and investor with more than two decades of experience, he has raised over $20 million for NovaScan, secured a CPRIT grant, and helped steer clinical trials in skin, lung, breast, GI and pancreatic cancers. Earlier in his career he helped shape companies including New Aera (acquired by Inogen), Merge Healthcare (IPO; later acquired by IBM), and OrthoScan, and was a partner at healthcare investment bank Healthios.
NovaScan
NovaScan is a Chicago-based clinical-stage oncology company building low-cost, point-of-care devices that detect cancer in real time. Its platform pairs spectral bioimpedance with machine learning around a single biophysical signal - the Cole relaxation frequency, which differs by orders of magnitude between cancerous and healthy tissue. Two lead products, nsCanary for assessing biopsy cores and MarginScan for checking surgical excision margins, aim to deliver answers in seconds instead of the days that conventional pathology can take.